profit from every $100 of sales.
$0$100
Cocrystal Pharma
$0.98-1.00% today
-4.8% in 1 year
1-year low $0.821-year high $1.57
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Cocrystal Pharma sold, what it kept, and what it did with the cash.
Sales went from $0 in 2022 to $0 in 2025, with -$8.83 million of profit last year.
SalesProfit
Cocrystal Pharma vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Cocrystal Pharma | No profit yet | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads Cocrystal Pharma's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 0 | 0 | |
| – | – | – | – | |
| -18 | -21 | -18 | -9 | |
| -18 | -21 | -17 | -9 | |
| -39 | -18 | -18 | -9 | |
| -4.77 | -1.87 | -1.72 | -0.78 | |
| – | – | – | – | |
| – | – | – | – | |
| – | – | – | – |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 41 | 31 | 13 | 10 |
| Cash | 37 | 26 | 10 | 7 |
| Total debt | 0 | 2 | 2 | 2 |
| Total liabilities | 1 | 5 | 4 | 3 |
| 40 | 26 | 10 | 6 | |
| 8 | 10 | 10 | 11 | |
| -35.9% | -59.2% | -124.7% | -90.9% | |
| -98.2% | -68.2% | -183.8% | -139.5% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -21 | -15 | -16 | -8 | |
| 0 | 0 | 0 | 0 | |
| -22 | -15 | -16 | -8 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 1 | 1 | 1 | 0 |
Valuation
- –
- –
- –
- 2.6×
- –
- –
- –
- -43.5%
- -46.8%
- 0.0%
Profitability
- 0.0%
- 0.0%
- 0.0%
- 0.0%
- -115.1%
- -89.3%
- -132.6%
- -90.9%
- -120.2%
- –
Growth
- –
- –
- +50.3%
- –
- +10.1%
Financial health
- 0.6×
- 0.24
- 15.5%
- –
- 3.68
- 3.68
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 21%of 871
Bottom 1%of 986
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 21, 2026 | -0.16 | -0.15 | −6.7% |
| May 15, 2026 | -0.17 | -0.15 | −13.3% |
| Nov 14, 2025 | -0.19 | -0.22 | +13.6% |
| Aug 14, 2025 | -0.20 | -0.30 | +33.3% |
| May 15, 2025 | -0.23 | -0.52 | +55.8% |
| Mar 31, 2025 | -0.32 | -0.55 | +41.8% |
| Nov 13, 2024 | -0.49 | -0.57 | +14.0% |
| Aug 14, 2024 | -0.53 | -0.51 | −3.9% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
24No pass
Benjamin Graham
44No pass
Philip Fisher
33No pass
Peter Lynch
56No pass
Joel Greenblatt
0No pass
Charlie Munger
27No pass
Terry Smith
27No pass
Questions about Cocrystal Pharma
Is Cocrystal Pharma a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Cocrystal Pharma AI analysis
What does Cocrystal Pharma do?
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It is in Biotechnology.
Does Cocrystal Pharma pay a dividend?
No. Cocrystal Pharma does not pay a dividend at the moment.
Is Cocrystal Pharma stock halal?
No. Cocrystal Pharma does not pass our halal screen: its cash and confirmed interest-bearing investments are 37% of its market value, at or above the 33% limit. How we check
How has Cocrystal Pharma stock done over the past year?
Down 4.8% over the past twelve months, to $0.98. It traded between $0.82 and $1.57 and is 37.6% below its high.
Who are Cocrystal Pharma's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Cocrystal Pharma's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.